Canadian Patents Database / Patent 2787472 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent Application: (11) CA 2787472
(54) English Title: PROTEIN KINASE INHIBITORS
(54) French Title: INHIBITEURS DE LA PROTEINE KINASE
(51) International Patent Classification (IPC):
  • C07D 215/42 (2006.01)
  • A61K 31/47 (2006.01)
  • A61K 31/4706 (2006.01)
  • C07D 215/20 (2006.01)
  • C07D 239/86 (2006.01)
  • C07D 401/12 (2006.01)
  • C07D 413/12 (2006.01)
  • C07D 417/12 (2006.01)
(72) Inventors :
  • LAURENT, ALAIN (Canada)
  • ROSE, YANNICK (Canada)
(73) Owners :
  • PHARMASCIENCE INC. (Canada)
(71) Applicants :
  • PHARMASCIENCE INC. (Canada)
(74) Agent: STIKEMAN ELLIOTT LLP
(74) Associate agent:
(45) Issued:
(22) Filed Date: 2012-08-22
(41) Open to Public Inspection: 2014-02-22
(30) Availability of licence: N/A
(30) Language of filing: English

English Abstract



The present invention relates to a novel family of inhibitors of protein
kinases. In particular, the present invention relates to inhibitors of the
members of the Tec and Src protein kinase families, more particularly Btk.


Note: Claims are shown in the official language in which they were submitted.


CLAIMS
1. A compound of Formula 1:
A-Y-E-W-Z (1)
wherein
A is selected from the group consisting of:
Image
X1 is selected from N or O;
X2 is selected from N or CH;
n is an integer from 0 to 2;
Y is selected from:
Image
E is selected from oxygen,
W is selected from:
Image
X1 is selected from hydrogen, halogen;
m1 and m2 are integers from 0 to 2;
R and Z are independently selected from:
1) alkyl,
2) aralkyl,
3) heteroaralkyl,
4) -OR3,
5) -OC(O)R4,
6) -OC(O)NR5R6,
7) -CH2O-R4,
39


8) -NR5R6,
9) -NR2C(O)R4,
10) -NR2S(O)n R4,
11) -NR2C(O)NR5R6;
wherein the alkyl, aralkyl and heteraralkyl may be further substituted;
R2 is selected from hydrogen or alkyl;
R3 is selected from substituted or unsubstituted alkyl, alkenyl, alkynyl,
heteroalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aralkyl or
heteroaralkyl;
R4 is selected from substituted or unsubstituted alkyl, alkenyl, alkynyl,
heteroalkyl, carbocyclyl, heterocyclyl, aryl or heteroaryl;
R5 and R6 are independently selected from hydrogen, alkyl, alkenyl,
alkynyl, heteroalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl or R5
and R6 can be fused to form a 3 to 8 membered heterocyclyl ring
system.
2. Compound according to claim 1 wherein Z is selected from -OR3 and
R3 is selected from substituted or unsubstituted aralkyl, or substituted or
unsubstituted heteroaralkyl.
3. Compounds according to claim 1 or 2, wherein A is selected from the
group consisting of:
Image
4. Compound according to any one of claims 1 to 3, wherein Z is selected
from the group consisting of:

Image
5. Compound according to any one of claims 1 to 4, wherein W is
selected from the group consisting of:
Image
6. Compound according to any one of claims 1 to 5, wherein W is
Image
7. Compound of the following structure:
Image
8. Compound of the following structure:
Image

41

9. Compound of the following structure:
Image
10. Compound of the following structure:
Image
11. Compound of the following structure:
Image
12. Compound of the following structure:
Image

42

13. Compound of the following structure:
Image
14. Compound of the following structure:
Image
15. Compound of the following structure:
Image

43

16. Compound of the following structure:
Image
17. Compound of the following structure:
Image
18. Compound of the following structure:
Image
19. Compound of the following structure:

44

Image
20. Compound of the following structure:
Image
21. Compound of the following structure:
Image
22. Compound of the following structure:
Image
23. Compound of the following structure:


Image

46

Note: Descriptions are shown in the official language in which they were submitted.

CA 02787472 2012-08-22
PROTEIN KINASE INHIBITORS
FIELD OF INVENTION
The present invention relates to a novel family of inhibitors of protein
kinases. In particular, the present invention relates to inhibitors of the
members of the Tec and Src protein kinase families, more particularly Btk.
BACKGROUND OF THE INVENTION
Protein kinases are a large group of intracellular and transmembrane
signaling proteins in eukaryotic cells. These enzymes are responsible for
transfer of the terminal (gamma) phosphate from ATP to specific amino acid
residues of target proteins. Phosphorylation of specific tyrosine, serine or
threonine amino acid residues in target proteins can modulate their activity
leading to profound changes in cellular signaling and metabolism. Protein
kinases can be found in the cell membrane, cytosol and organelles such as
the nucleus and are responsible for mediating multiple cellular functions
including metabolism, cellular growth and division, cellular signaling,
modulation of immune responses, and apoptosis. The receptor tyrosine
kinases are a large family of cell surface receptors with protein tyrosine
kinase activity that respond to extracellular cues and activate intracellular
signaling cascades (Plowman et at. (1994) DN&P, 7(6):334-339).
Aberrant activation or excessive expression of various protein kinases are
implicated in the mechanism of multiple diseases and disorders
characterized by benign and malignant proliferation, excess angiogenesis, as
well as diseases resulting from inappropriate activation of the immune
system. Thus, inhibitors of select kinases or kinase families are expected to
be useful in the treatment of cancer, autoimmune diseases, and
inflammatory conditions including, but not limited to: solid tumors,
hematological malignancies, arthritis, graft versus host disease, lupus
erythematosus, psoriasis, colitis, illeitis, multiple sclerosis, uveitis,
coronary
artery vasculopathy, systemic sclerosis, atherosclerosis, asthma, transplant
rejection, allergy, dermatomyositis, pemphigus and the like.
2

CA 02787472 2012-08-22
Examples of kinases that can be targeted to modulate disease include
receptor tyrosine kinases such as members of the platelet-derived growth
factor receptor (PDGFR), vascular endothelial growth factor receptor (VEGFR)
families and intracellular proteins such as members of the Syk, SRC, and Tec
families of kinases.
Tec kinases are non-receptor tyrosine kinases predominantly, but not
exclusively, expressed in cells of hematopoietic origin (Bradshaw JM. Cell
Signal. 2010,22:1175-84). The Tec family includes Tec, Bruton's tyrosine
kinase (Btk), inducible T-cell kinase (Itk), resting lymphocyte kinase
(RIk/Txk), and bone marrow-expressed kinase (Bmx/Etk). Btk is a Tec
family kinase which is important in B-cell receptor signaling. Btk is
activated
by Src-family kinases and phosphorylates PLC gamma leading to effects on
B-cell function and survival. Additionally, Btk is important in signal
transduction in response to immune complex recognition by macrophage,
mast cells and neutrophils. Btk inhibition is also important in survival of
lymphoma cells (Herman, SEM. Blood 2011, 117:6287-6289) suggesting that
inhibition of Btk may be useful in the treatment of lymphomas. As
such,
inhibitors of Btk and related kinases are of great interest as anti-
inflammatory as well as anti-cancer agents.
cSRC is the prototypical member of the SRC family of tyrosine kinases which
includes Lyn, Fyn, Lck, Hck, Fgr, Blk, Syk, Yrk, and Yes. cSRC is critically
involved in signaling pathways involved in cancer and is often over-expressed
in human malignancies (Kim LC, Song L, Haura EB. Nat Rev Clin Oncol. 2009
6(10):587-9). The role of cSRC in cell adhesion, migration and bone
remodeling strongly implicate this kinase in the development and progression
of bone metastases. cSRC is also involved in signaling downstream of
growth factor receptor tyrosine kinases and regulates cell cycle progression
suggesting that cSRC inhibition would impact cancer cell proliferation.
Additionally, inhibition of SRC family members may be useful in treatments
designed to modulate immune function. SRC family members, including Lck,
regulate T-cell receptor signal transduction which leads to gene regulation
3

CA 02787472 2012-08-22
events resulting in cytokine release, survival and proliferation. Thus,
inhibitors of Lck have been keenly sought as immunosuppressive agents with
potential application in graft rejection and T-cell mediated autoimmune
disease (Martin et al. Expert Opin Ther Pat. 2010, 20:1573-93).
Inhibition of kinases using small molecule inhibitors has successfully led to
several approved therapeutic agents used in the treatment of human
conditions. Herein, we disclose a novel family of kinase inhibitors. Further,
we demonstrate that modifications in compound substitution can influence
kinase selectivity and therefore the biological function of that agent.
SUMMARY OF THE INVENTION
The present invention relates to a novel family of kinase inhibitors.
Compounds of this class have been found to have inhibitory activity against
members of the Tec and Scr protein kinase families, more particularly Btk.
One aspect of the present invention is directed to a compound of Formula 1:
(1)
wherein
A is selected from the group consisting of:
X2
(R)n-i II
-
Xl is selected from N or 0;
X2 is selected from N or CH;
n is an integer from 0 to 2;
Y is selected from:
4

CA 02787472 2012-08-22
,
1 =1
(X2)ml
E is selected from oxygen,
W is selected from:
..,(Xl)rn2
I
'llt. .rri
X1 is selected from hydrogen, halogen;
ml and m2 are integers from 0 to 2;
R and Z are independently selected from:
1) alkyl,
2) aralkyl,
3) heteroaralkyl,
4) -0R3,
5) -0C(0)R4,
6) -0C(0)NR5R6,
7) -CH2O-R4,
8) -NR5R6,
9) -NR2C(0)R4,
10) -NR2S(0)nR4,
11) -NR2C(0)NR5R6;
wherein the alkyl, aralkyl and heteraralkyl may be further
substituted;

CA 02787472 2012-08-22
R2 is selected from hydrogen or alkyl;
R3 is selected from substituted or unsubstituted alkyl, alkenyl,
alkynyl, heteroalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl,
aralkyl or heteroaralkyl;
R4 is selected from substituted or unsubstituted alkyl, alkenyl,
alkynyl, heteroalkyl, carbocyclyl, heterocyclyl, aryl or
heteroaryl;
R5 and R6 are independently selected from hydrogen, alkyl,
alkenyl, alkynyl, heteroalkyl, carbocyclyl, heterocyclyl, aryl,
heteroaryl or R5 and R6 can be fused to form a 3 to 8 membered
heterocyclyl ring system.
Preferred embodiment includes compounds of Formula 1 where Z is selected
from -0R3 and R3 is selected from substituted or unsubstituted aralkyl, or
substituted or unsubstituted heteroaralkyl.
Preferred embodiment includes compounds of Formula 1 where A is selected
from the group consisting of:
HNA )L
0
0 0
ilo 1 I. I
0 Ni 0 N ,
Preferred embodiment includes compounds of Formula 1 where Z is selected
from the group consisting of:
N
\\ F3C N \\
F3C
. 5 ____ JO . _/0 10+
-10 S. -0 . -CI i
i t f i i
,-N o/ -- 1.--N or_o/ ---N1
i
¨--N
\s II 1 N
, / .
6

CA 02787472 2012-08-22
, .
More preferred embodiment includes compounds of Formula 1 where W is
selected from the group consisting of:
/ \ j
-0 0 -0 N
; and / .
More preferred embodiment includes compounds of Formula 1 where W is
selected from the group consisting of:
lz.
F
cc
,, 0 cs
.
Another aspect of the present invention provides a pharmaceutical
composition comprising an effective amount of a compound of Formula 1 and
a pharmaceutically acceptable carrier, diluent or excipient.
In another aspect of the present invention, there is provided a use of the
compound of Formula 1 as an inhibitor of protein kinase, more particularly,
as an inhibitor of Btk.
Another aspect of the present invention provides a method of modulating
kinase function, the method comprising contacting a cell with a compound of
the present invention in an amount sufficient to modulate the enzymatic
activity of a given kinase or kinases, such as Btk, thereby modulating the
kinase function.
Another aspect of the present invention provides a method of modulating the
target kinase function, the method comprising a) contacting a cell with a
compound of the present invention in an amount sufficient to modulate the
target kinase function, thereby b) modulating the target kinase activity and
signaling.
Another aspect of the present invention provides a probe, the probe
comprising a compound of Formula 1 labeled with a detectable label or an
7

CA 02787472 2012-08-22
affinity tag. In other words, the probe comprises a residue of a compound of
Formula 1 covalently conjugated to a detectable label. Such detectable
labels include, but are not limited to, a fluorescent moiety, a
chemiluminescent moiety, a paramagnetic contrast agent, a metal chelate, a
radioactive isotope-containing moiety, or biotin.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
The present invention relates to novel kinase inhibitors. These compounds
are found to have activity as inhibitors of protein kinases: including members

of the tyrosine kinases Aurora, SRC (more specifically Lck) and Tec (more
specifically Btk) kinase families.
Compounds of the present invention may be formulated into a
pharmaceutical composition which comprises an effective amount of a
compound of Formula 1 with a pharmaceutically acceptable diluent or carrier.
For example, the pharmaceutical compositions may be in a conventional
pharmaceutical form suitable for oral administration (e.g., tablets, capsules,

granules, powders and syrups), parenteral administration (e.g., injections
(intravenous, intramuscular, or subcutaneous)), drop infusion preparations,
inhalation, eye lotion, topical administration (e.g., ointment), or
suppositories.
Regardless of the route of administration selected the
compounds may be formulated into pharmaceutically acceptable dosage
forms by conventional methods known to those skilled in the art.
The phrase "pharmaceutically acceptable" is employed herein to refer to
those ligands, materials, compositions, and/or dosage forms which are,
within the scope of sound medical judgment, suitable for use in contact with
the tissues of human beings and animals without excessive toxicity,
irritation, allergic response, or other problem or complication, commensurate
with a reasonable benefit/risk ratio.
The phrase "pharmaceutically acceptable carrier" as used herein means a
pharmaceutically acceptable material, composition, or vehicle, such as a
liquid or solid filler, diluent, excipient, solvent or encapsulating material.
8

CA 02787472 2012-08-22
Each carrier must be acceptable in the sense of being compatible with the
other ingredients of the formulation, including the active ingredient, and not
injurious or harmful to the patient. Some examples of materials which can
serve as pharmaceutically acceptable carriers include: (1) sugars, such as
lactose, glucose, and sucrose; (2) starches, such as corn starch, potato
starch, and substituted or unsubstituted B-cyclodextrin; (3) cellulose, and
its
derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and
cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc;
(8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as
peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil,
and
soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as
glycerin, sorbitol, mannitol, and polyethylene glycol; (12) esters, such as
ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as
magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16)
pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl
alcohol; (20) phosphate buffer solutions; and (21) other non-toxic
compatible substances employed in pharmaceutical formulations.
The term "pharmaceutically acceptable salt" refers to the relatively non-
toxic,
inorganic and organic acid addition salts of the compound(s). These salts
can be prepared in situ during the final isolation and purification of the
compound(s), or by separately reacting a purified compound(s) in its free
base form with a suitable organic or inorganic acid, and isolating the salt
thus
formed.
Representative salts include the hydrobromide, hydrochloride,
sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate,
stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate,
fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate,
lactobionate, laurylsulphonate salts, and amino acid salts, and the like (See,

for example, Berge et al. (1977) "Pharmaceutical Salts", J. Pharm. Sci. 66:
1-19).
In other cases, the compounds of the present invention may contain one or
more acidic functional groups and, thus, are capable of forming
9

CA 02787472 2012-08-22
pharmaceutically acceptable salts with pharmaceutically acceptable bases.
The term "pharmaceutically acceptable salts" in these instances refers to the
relatively non-toxic inorganic and organic base addition salts of a
compound(s). These salts can likewise be prepared in situ during the final
isolation and purification of the compound(s), or by separately reacting the
purified compound(s) in its free acid form with a suitable base, such as the
hydroxide, carbonate, or bicarbonate of a pharmaceutically acceptable metal
cation, with ammonia, or with a pharmaceutically acceptable organic
primary, secondary, or tertiary amine. Representative alkali or alkaline earth

salts include the lithium, sodium, potassium, calcium, magnesium, and
aluminum salts, and the like. Representative organic amines useful for the
formation of base addition salts include ethylamine, diethylamine,
ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like
(see, for example, Berge et al., supra).
As used herein, the term "affinity tag" means a ligand or group, linked either

to a compound of the present invention or to a protein kinase domain, that
allows the conjugate to be extracted from a solution.
The term "alkyl" refers to substituted or unsubstituted saturated hydrocarbon
groups, including straight-chain alkyl and branched-chain alkyl groups,
including haloalkyl groups such as trifluoromethyl and 2,2,2-trifluoroethyl,
etc. Representative alkyl groups include methyl, ethyl, n-propyl, isopropyl,
n-butyl, t-butyl, isobutyl, sec-butyl, (cyclohexyl)methyl, cyclopropylmethyl,
n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. The terms "alkenyl" and
"alkynyl" refer to substituted or unsubstituted unsaturated aliphatic groups
analogous in length and possible substitution to the alkyls described above,
but that contain at least one double or triple bond respectively.
Representative alkenyl groups include vinyl, propen-2-yl, crotyl, isopenten-2-
yl, 1,3-butadien-2-y1), 2,4-pentadienyl, and 1,4-
pentadien-3-yl.
Representative alkynyl groups include ethynyl, 1- and 3-propynyl, and 3-
butynyl. In certain preferred embodiments, alkyl substituents are lower alkyl
groups, e.g., having from 1 to 6 carbon atoms. Similarly, alkenyl and alkynyl

CA 02787472 2012-08-22
preferably refer to lower alkenyl and alkynyl groups, e.g., having from 2 to 6

carbon atoms. As used herein, "alkylene" refers to an alkyl group with two
open valencies (rather than a single valency), such as -(CH2)1_10- and
substituted variants thereof.
The term "alkoxy" refers to an alkyl group having an oxygen attached
thereto. Representative alkoxy groups include methoxy, ethoxy, propoxy,
tert-butoxy and the like. An "ether" is two hydrocarbons covalently linked by
an oxygen. Accordingly, the substituent of an alkyl that renders that alkyl an

ether is or resembles an alkoxy.
The term "alkoxyalkyl" refers to an alkyl group substituted with an alkoxy
group, thereby forming an ether.
The terms "amide" and "amido" are art-recognized as an amino-substituted
carbonyl and includes a moiety that can be represented by the general
formula:
0
).(
R9
wherein R9, Fe are as defined above. Preferred embodiments of the amide
will not include imides, which may be unstable.
The terms "amine" and "amino" are art-recognized and refer to both
unsubstituted and substituted amines and salts thereof, e.g., a moiety that
can be represented by the general formulae:
R9 R9
1+
¨14 or ¨N¨R1
NR10
wherein R9, Fe and Fen' each independently represent a hydrogen, an alkyl,
an alkenyl, -(CH2)m-R8, or R9 and Fe taken together with the N atom to
which they are attached complete a heterocycle having from 4 to 8 atoms in
11

CA 02787472 2012-08-22
,
the ring structure; R8 represents an aryl, a cycloalkyl, a cycloalkenyl, a
heterocyclyl or a polycyclyl; and m is zero or an integer from 1 to 8. In
preferred embodiments, only one of R9 or R' can be a carbonyl, e.g., R9, R10,

and the nitrogen together do not form an imide. In even more preferred
embodiments, R9 and Rl (and optionally 11' ') each independently represent
a hydrogen, an alkyl, an alkenyl, or -(CH2)m-R8. In certain embodiments, the
amino group is basic, meaning the protonated form has a pK, > 7.00.
The term "aralkyl", as used herein, refers to an alkyl group substituted with
an aryl group, for example -(CH2)n-Ar.
The term "heteroaralkyl", as used herein, refers to an alkyl group substituted

with a heteroaryl group, for example -(CH2)n-Het.
The term "aryl" as used herein includes 5-, 6-, and 7-membered substituted
or unsubstituted single-ring aromatic groups in which each atom of the ring
is carbon. The term "aryl" also includes polycyclic ring systems having two
or more cyclic rings in which two or more carbons are common to two
adjoining rings wherein at least one of the rings is aromatic, e.g., the other

cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls,
heteroaryls, and/or heterocyclyls. Aryl groups include benzene, naphthalene,
phenanthrene, phenol, aniline, anthracene, and phenanthrene.
The terms "carbocycle" and "carbocyclyl", as used herein, refer to a non-
aromatic substituted or unsubstituted ring in which each atom of the ring is
carbon. The terms "carbocycle" and "carbocycly1" also include polycyclic ring
systems having two or more cyclic rings in which two or more carbons are
common to two adjoining rings wherein at least one of the rings is
carbocyclic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls,
cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls.
Representative
carbocyclic groups include cyclopentyl, cyclohexyl, 1-cyclohexenyl, and 3-
cyclohexen-1-yl, cycloheptyl.
The term "carbonyl" is art-recognized and includes such moieties as can be
represented by the general formula:
12

CA 02787472 2012-08-22
=
0
wherein X is a bond or represents an oxygen or a sulfur, and Rn represents a
hydrogen, an alkyl, an alkenyl, -(CH2)m-R8 or a pharmaceutically acceptable
salt. Where X is an oxygen and R11 is not hydrogen, the formula represents
an "ester". Where X is an oxygen, and R11 is a hydrogen, the formula
represents a "carboxylic acid".
The terms "heteroaryl" includes substituted or unsubstituted aromatic 5- to
7-membered ring structures, more preferably 5- to 6-membered rings,
whose ring structures include one to four heteroatoms. The
term
"heteroaryl" also includes polycyclic ring systems having two or more cyclic
rings in which two or more carbons are common to two adjoining rings
wherein at least one of the rings is heteroaromatic, e.g., the other cyclic
rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls,
and/or heterocyclyls. Heteroaryl groups include, for example, pyrrole, furan,
thiophene, imidazole, isoxazole, oxazole, thiazole, triazole, pyrazole,
pyridine, pyrazine, pyridazine and pyrimidine, and the like.
The term "heteroatom" as used herein means an atom of any element other
than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, and
sulfur.
The terms "heterocycly1" or "heterocyclic group" refer to substituted or
unsubstituted non-aromatic 3- to 10-membered ring structures, more
preferably 3- to 7-membered rings, whose ring structures include one to four
heteroatoms. The term terms "heterocycly1" or "heterocyclic group" also
include polycyclic ring systems having two or more cyclic rings in which two
or more carbons are common to two adjoining rings wherein at least one of
the rings is heterocyclic, e.g., the other cyclic rings can be cycloalkyls,
cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls.
Heterocyclyl groups include, for example, tetrahydrofuran, tetrahydropyran,
piperidine, piperazine, pyrrolidine, morpholine, lactones, and lactams.
13

CA 02787472 2012-08-22
The term "hydrocarbon", as used herein, refers to a group that is bonded
through a carbon atom that does not have a =0 or =S substituent, and
typically has at least one carbon-hydrogen bond and a primarily carbon
backbone, but may optionally include heteroatoms. Thus, groups like
methyl, ethoxyethyl, 2-pyridyl, and trifluoromethyl are considered to be
hydrocarbyl for the purposes of this application, but substituents such as
acetyl (which has a =0 substituent on the linking carbon) and ethoxy (which
is linked through oxygen, not carbon) are not. Hydrocarbyl groups include,
but are not limited to aryl, heteroaryl, carbocycle, heterocycle, alkyl,
alkenyl,
alkynyl, and combinations thereof.
The terms "polycycly1" or "polycyclic" refer to two or more rings (e.g.,
cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or
heterocyclyls) in which two or more carbons are common to two adjoining
rings, e.g., the rings are "fused rings". Each of the rings of the polycycle
can
be substituted or unsubstituted.
As used herein, the term "probe" means a compound of the invention which
is labeled with either a detectable label or an affinity tag, and which is
capable of binding, either covalently or non-covalently, to a protein kinase
domain. When, for example, the probe is non-covalently bound, it may be
displaced by a test compound. When, for example, the probe is bound
covalently, it may be used to form cross-linked adducts, which may be
quantified and inhibited by a test compound.
The term "substituted" refers to moieties having substituents replacing a
hydrogen on one or more carbons of the backbone. It will be understood
that "substitution" or "substituted with" includes the implicit proviso that
such substitution is in accordance with permitted valence of the substituted
atom and the substituent, and that the substitution results in a stable
compound, e.g., which does not spontaneously undergo transformation such
as by rearrangement, cyclization, elimination, etc. As used herein, the term
"substituted" is contemplated to include all permissible substituents of
organic compounds. In a broad aspect, the permissible substituents include
14

CA 02787472 2012-08-22
acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic,
aromatic and non-aromatic substituents of organic compounds. The
permissible substituents can be one or more and the same or different for
appropriate organic compounds. For
purposes of this invention, the
heteroatoms such as nitrogen may have hydrogen substituents and/or any
permissible substituents of organic compounds described herein which satisfy
the valences of the heteroatoms. Substituents can include, for example, a
halogen, a hydroxyl, a carbonyl (such as a carboxyl, an alkoxycarbonyl, a
formyl, or an acyl), a thiocarbonyl (such as a thioester, a thioacetate, or a
thioformate), an alkoxyl, a phosphoryl, a phosphate, a phosphonate, a
phosphinate, an amino, an amido, an amidine, an imine, a cyano, a nitro, an
azido, a sulfhydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, a
sulfonamido, a sulfonyl, a heterocyclyl, an aralkyi, or an aromatic or
heteroaromatic moiety. It will be understood by those skilled in the art that
the moieties substituted on the hydrocarbon chain can themselves be
substituted, if appropriate.
Compounds of the invention also include all isotopes of atoms present in the
intermediates and/or final compounds. Isotopes include those atoms having
the same atomic number but different mass numbers. For example, isotopes
of hydrogen include deuterium and tritium.
General Synthetic Methods
General Synthetic Method A:
x
ci 40 HN 0 X
Base, ligand, HN 40 1
NH20 catalyst O Z io
0 N 0 N v Z o 40 1,r
,,,--ci.yõ,
X=Br, I OH
Scheme 1

CA 02787472 2012-08-22
Exemplification
The following synthetic methods are intended to be representative of the
chemistry used to prepare compounds of Formula 1 and are not intended to
be limiting.
Synthesis of Compound 3:
CHO 5 CHO
TEA, TBDMSCI NaBH4 5 OH
______________________ p. _________________ ).
OH OTBS OTBS
2-a 2-b 2-c
Ph3P, DIAD, 0 0 St TBAF 0 0
2-c ____________ 1. CN p CN
110 OTBS OH
HO
2-d 2-e
CN
I
CI 40 HN 40 I, 0 40
ii HN 0
NH2 2c, io ,N '''OH O
' 0411, 1
0 N 'ID N Cul, Cs2CO3 CN
N
2-f 21 Compound 3
Scheme 2
Step 1: Intermediate 2-b
To a solution of 3-hydroxybenzaldehyde (14.73 g, 121 mmol) in
dichloromethane (100 mL) were sequentially added triethylamine (25.08 ml,
181 mmol), tert-butylchlorodimethylsilane (20.0 g, 133 mmol), portion wise,
and the reaction was stirred at room temperature overnight. 10% Citric acid
was added, the organic layer was separated, washed with brine, dried over
16

CA 02787472 2012-08-22
, .
MgSO4, filtered and concentrated under reduced pressure. Purification by
silica gel chromatography provided intermediate 2-b as a yellow oil.
Step 2: Intermediate 2-c
To a solution of intermediate 2-b (16.0 g, 67.7 mmol) in methanol (100 ml)
cooled to 0 C was added portion wise sodium borohydride (1.28 g, 33.8
mmol). After the addition was completed the reaction was stirred at room
temperature for 2 hours. Volatiles were removed under reduced pressure.
Water and ethyl acetate were added to the residue, the organic layer was
separated, washed with brine, dried over MgSO4, filtered and concentrated
under reduced pressure to provide intermediate 2-c as yellow oil.
Step 3: Intermediate 2-d
To a solution of intermediate 2-c (1.0 g, 2.09 mmol) in THF (42 mL) were
sequentially added 2-hydroxybenzonitrile (600 mg, 5.03 mmol),
triphenylphosphine (1.32 g, 5.03 mmol) and DIAD (991 pl, 5.03 mmol) drop
wise at room temperature; the reaction was stirred at reflux for 2 hours then
cooled to room temperature. A saturated aqueous solution of ammonium
chloride and ethyl acetate were added, the organic layer was separated,
washed with brine, dried over MgSO4, filtered and concentrated under
reduced pressure. Purification by silica gel chromatography provided
intermediate 2-d as a colorless oil.
Step 4: Intermediate 2-e
To a solution of intermediate 2-d (1.22 g, 3.62 mmol) in THF (36.0 ml) was
added tetrabutylammonium fluoride (946 mg, 3.62 mmol) and the reaction
was stirred at room temperature for 1 hour. A saturated aqueous solution of
ammonium chloride and ethyl acetate were added, the organic layer was
separated, washed with brine, dried over MgSO4, filtered and concentrated
17

CA 02787472 2012-08-22
under reduced pressure. Purification by silica gel chromatography provided
intermediate 2-e as a white solid.
Step 5: Intermediate 2-g
To a solution of 4-iodoaniline (1 g, 4.57 mmol), 4-chloro-6,7-
dimethoxyquinoline (1.12 g, 5.02 mmol) in iPrOH (22.8 ml) was added 4N
HCI in 1,4-dioxane (0.57 ml, 2.28 mmol) and the reaction was heated in a
sealed tube at 120 C for 1 hour. Volatiles were removed under reduced
pressure. Me0H and ethyl acetate were added to the residue; a precipitate
formed and was collected by filtration to provide intermediate 2-g as white
solid.
Step 6: Compound 3
To a solution of intermediate 2-e (178 mg, 0.79 mmol), intermediate 2-g
(200 mg, 0.45 mmol) in 1,4-dioxane, was added cesium carbonate (294 mg,
0.90 mmol), N-N-dimethylaminoglycine (14 mg, 0.13 mmol) and copper (I)
iodide (17 mg, 0.09 mmol). The reaction was degassed with argon for 10
minutes, stired at reflux for 36 hours and then cooled to room temperature.
Water and ethyl acetate were added, the organic layer was separated, the
aqueous layer was extracted twice with ethyl acetate, the combined organic
extracts were washed with brine, dried over MgSO4, filtered and concentrated
under reduced pressure. Purification by reverse phase chromatography
eluting with 1% HCl/methanol gradient provided compound 3=HCI as beige
solid. MS (m/z) M+H= 504.2
Synthesis of Compound 4:
18

CA 02787472 2012-08-22
Imidazole 40 OH TBAFHO 4 OH TBDMSCI Ph3P, DIAD
, N
OH OTBDMS OTBDMS OH
3-a 3-b 3-c 3-d
Ojs
HN 0
HN =
______________________________________ ,0
0 S N c.,, 0s2003
3-d Compound 4
2-g
Scheme 3
Step 1: Intermediate 3-b
To a solution of Resorcinol (11.83 g, 107 mmol) in DMF (50 ml) cooled to
0 C was added imidazole (15.36 g, 226 mmol) and tert-
butylchlorodimethylsilane (17.0 g, 113 mmol). The reaction was then stirred
at room temperature overnight. A saturated aqueous solution of ammonium
chloride and ethyl acetate were added, the organic layer was separated,
washed 3 times with a saturated aqueous solution of ammonium chloride and
brine, dried over MgSO4, filtered and concentrated under reduced pressure.
Purification by silica gel chromatography provided intermediate 3-b as
colorless oil.
Step 2: Intermediate 3-c
To a solution of intermediate 3-b (1.94 g, 8.68 mmol) and thiazol-5-
ylmethanol (1.0 g, 8.68 mmol) in THF (20 ml) were sequentially added
triphenylphosphine (3.42 g, 13.0 mmol) and DIAD (2.52 ml, 13.0 mmol) at
room temperature and the reaction was then stirred at room temperature
19

CA 02787472 2012-08-22
. .
overnight. Volatiles were removed under reduced pressure. Purification by
silica gel chromatography provided intermediate 3-c as yellow oil.
Step 3: Intermediate 3-d
To a solution of intermediate 3-c (1.60 g, 4.98 mmol) in THF (20 ml) was
added a 1.0 M solution of TBAF in THF (5.47 ml, 5.47 mmol) and the reaction
was stirred at room temperature for 1 hour. A saturated aqueous solution of
ammonium chloride and ethyl acetate were added, the organic layer was
separated, washed with brine, dried over MgSO4, filtered and concentrated
under reduced pressure. Diethyl ether was added to the residue; a
precipitate formed and was collected by filtration to provide intermediate 3-d

as white solid.
Step 4: Compound 4
To a solution of intermediate 3-d (100 mg, 0.48 mmol), intermediate 2-g
(175 mg, 0.43 mmol) in 1,4-dioxane, was added cesium carbonate (314 mg,
0.96 mmol), N-N-dimethylaminoglycine (50 mg, 0.48 mmol) and copper (I)
iodide (33 mg, 0.17 mmol). The reaction was degassed with argon for 10
minutes, stirred at reflux for 24 hours and then cooled to room temperature.
Water and ethyl acetate were added, the organic layer was separated, the
aqueous layer was extracted twice with ethyl acetate, the combined organic
extracts were washed with brine, dried over MgSO4, filtered and concentrated
under reduced pressure. Purification by reverse phase chromatography
eluting with 1% HCl/methanol gradient provided compound 4.1-1C1 as beige
solid. MS (m/z) M+H= 486.1

CA 02787472 2012-08-22
Synthesis of Compound 7:
40 ___________________ = __ 00 OH Cs2CO3 NC io 0 TBAF NC
0
= OTBDMS Br OTBDMS OH
3-b 4-a 4-b
is 0 1401
NC
I 0
' 40
HN NJ

OH HN
0
0
401 Cul, Cs2CO3
0 0
4-b
2-g Compound 7
Scheme 4
Step 1: Intermediate 4-a
To a solution of 2-(bromomethyl)benzonitrile (2.01 g, 10.25 mmol) and
intermediate 3-b (2.30 g, 10.25 mmol) in acetone (103 ml) was added
cesium carbonate (6.68 g, 20.50 mmol) and the reaction was stirred at reflux
for 2 hours and then cooled to toom temperature. A saturated aqueous
solution of ammonium chloride and ethyl acetate were added, the organic
layer was separated, washed with brine, dried over MgSO4, filtered and
concentrated under reduced pressure. Purification by silica gel
chromatography provided intermediate 4-a as yellow oil.
Step 2: Intermediate 4-b
To a solution of intermediate 4-a (3.40 g, 10.01 mmol) in THF (40 ml) was
added a 1.0 M solution of TBAF in THE (10.01 ml, 10.01 mmol) and the
reaction was stirred at room temperature for 30 minutes. A saturated
21

CA 02787472 2012-08-22
aqueous solution of ammonium chloride and ethyl acetate were added, the
organic layer was separated, washed with brine, dried over MgSO4, filtered
and concentrated under reduced pressure. Purification by silica gel
chromatography provided intermediate 4-b as yellow oil.
Step 3: Compound 7
To a solution of intermediate 4-b (102 mg, 0.45 mmol), intermediate 2-g
(200 mg, 0.45 mmol) in dioxane, was added cesium carbonate (294 mg,
0.90 mmol), N-N-dimethylaminoglycine (14 mg, 0.13 mmol) and copper (I)
iodide (17 mg, 0.09 mmol). The reaction was degassed with argon for 10
minutes, stirred at reflux for 24 hours and then cooled to room temperature.
Water and ethyl acetate were added, the organic layer was separated, the
aqueous layer was extracted twice with ethyl acetate, the combined organic
extracts were washed with brine, dried over MgSO4, filtered and concentrated
under reduced pressure. Purification by reverse phase chromatography
eluting with 1% HCl/methanol gradient provided compound 7=FICI as yellow
solid. MS (m/z) M+H= 504.1
Synthesis of Compound 13:
H2N LiAIH4 HO
CI
HC(0)0Et 0 toluene, reflux 0 S
5-a 5-b 5-c 54
F 0A,Ae Base
; OH ph DAD F TBAF
BBr3 F TBDMSCI io 3p , .0 S F ______ 0
OMe
OH OTBDMS OTBDMS 01-1
5-e 5-f 5-9 5-h 5-1
HN 40F 0
-)43)1'0H
0 0
N- Cul, Cs2CO3
FIN
0 Compound 8
0 N
Scheme 5
22

CA 02787472 2012-08-22
Step 1: Intermediate 5-b
Ethyl chloroacetate (50.0 g, 0.41 mol) and ethyl formate (30.2 g, 0.41 mol)
were taken in anhydrous toluene (500 mL) and cooled to 0 C. Sodium
ethoxide (35.1 g, 0.49 mol) was added portion wise. The reaction mixture
was stirred at 0 C for 5 hours and then at room temperature overnight. The
reaction mixture was quenched with water (250 mL) and washed twice with
diethyl ether. The aqueous layer was cooled to 0 C and acidified to pH 4-5
using 1 N HCI. The aqueous layer was extracted twice with diethyl ether; the
combined organic layers were dried over MgSO4 filtered and concentrated
under reduced pressure to provide intermediate 5-b as beige oil.
Step 2: Intermediate 5-c
To a solution of ethyl 2-chloro-3-oxopropanoate 5-b (34.7 g, 230 mmol) in
toluene (250 ml) was added thioacetamide (26.0 g, 346.0 mmol). The
reaction was stirred at 90 C overnight and then cooled to room temperature,
diluted with water (300 mL) and then neutralized to PH=7 with a saturated
aqueous solution of NaHCO3. Ethyl acetate was added, the organic layer was
separated, washed with brine, dried over MgSO4, filtered and concentrated
under reduced pressure. Purification by silica gel chromatography provided
intermediate 5-c as beige oil.
Step 3: Intermediate 5-d
To a solution of intermediate 5-c (22.2 g, 130.0 mmol) in THF (430 ml)
cooled to 0 C was added a 1.0 M solution L1AIH4 in THF (91.0 ml, 91.0 mmol)
and the solution was slowly warmed to room temperature and stirred for 2
hours. Water (3.5 ml) was slowly added, followed by 3.5 ml 15% NaOH (3.5
ml) and water (10.5 ml) and the mixture was stirred for 1 hour. The reaction
was filtered over celite and volatiles were removed under reduced pressure
to provide intermediate 5-d as yellow oil.
23

CA 02787472 2012-08-22
Step 4: Intermediate 5-f
To a solution of 1-fluoro-3,5-dirnethoxybenzene (12.5 g, 80 mmol) in
dichloromethane (80 ml) cooled to 00C was added dropwise over a period of
30 minutes a 1.0 M solution of BBr3 in dichloromethane (200 ml, 200 mmol).
The reaction was stirred for 1 hour at 0 C and then slowly warmed to room
temperature and stirred for 18 hours. The reaction was cooled to 0 C and
quenched by slow addition of Me0H and water. After stirring at room
temperature for 1 hour the mixture was filtered and volatiles were removed
under reduced pressure. Ethyl acetate was added to the residue; a
precipitate formed and was collected by filtration to provide intermediate 5-f

as orange solid.
Step 5: Intermediate 5-g
To a solution of intermediate 5-f (10.25 g, 80.0 mmol) in DMF (50 ml) cooled
to 0 C was added imidazole (5.99 g, 88.0 mmol) and tert-
butylchlorodimethylsilane (13.27 g, 88.0 mmol). The reaction was then
stirred at room temperature overnight. A saturated aqueous solution of
ammonium chloride and ethyl acetate were added, the organic layer was
separated, washed 3 times with a saturated aqueous solution of ammonium
chloride and brine, dried over MgSO4, filtered and concentrated under
reduced pressure. Purification by silica gel chromatography provided
intermediate 5-g as yellow oil.
Step 6: Intermediate 5-h
To a solution of intermediate 5-g (1.0 g, 105.0 mmol) and intermediate 5-d
(352 mg, 2.73 mmol) in THE (20 ml) were sequentially added
triphenylphosphine (1.07 g, 4.1 mmol) and DIAD (796 pl, 4.1 mmol) at room
temperature and the reaction was then stirred at room temperature for 1
hour. Volatiles were removed under reduced pressure. Purification by silica
gel chromatography provided intermediate 5-h as yellow oil.
24

CA 02787472 2012-08-22
Step 7: Intermediate 5-i
To a solution of intermediate 5-h (750 mg, 1.57 mmol) in THF (20 ml) was
added a 1.0 M solution of TBAF in THF (1.72 ml, 1.72 mmol) and the reaction
was stirred at room temperature for 1 hour. A saturated aqueous solution of
ammonium chloride and ethyl acetate were added, the organic layer was
separated, washed with brine, dried over MgSO4, filtered and concentrated
under reduced pressure. Diethyl ether was added to the residue; a
precipitate formed and was collected by filtration to provide intermediate 5-i

as white solid.
Step 8: Compound 8
To a solution of intermediate 5-i (133 mg, 0.56 mmol), intermediate 5-j
(227 mg, 0.56 mmol) in 1,4-dioxane, was added cesium carbonate (544 mg,
1.67 mmol), N-N-dimethylaminoglycine (86 mg, 0.83 mmol) and copper (I)
iodide (53 mg, 0.28 mmol). The reaction was degassed with argon for 10
minutes, stirred at reflux for 24 hours and then cooled to room temperature.
Water and ethyl acetate were added, the organic layer was separated, the
aqueous layer was extracted twice with ethyl acetate, the combined organic
extracts were washed with brine, dried over MgSO4, filtered and concentrated
under reduced pressure. Purification by reverse phase chromatography
eluting with 1% HCl/methanol gradient provided compound 8=HCI as yellow
solid. MS (m/z) M+H= 518.2

CA 02787472 2012-08-22
Synthesis of Compound 9:
, N
LiA11-14 H0j-
0
6-a 6-b
Ph3P, DIAD TBAF
5-g F 0
, N
--- OTBDMS OH
6-c 6-d
Ojor\--
HN I 0
0 Nj*LOH 0
ON40Cul, Cs2CO3 HN
2-g 6-d 0 Compound 9
Scheme 6
Step 1: Intermediate 6-b
To a solution of intermediate 6-a (2.0 g, 12.89 mmol) in THF (65 ml) cooled
to 0 C was added a 1.0 M solution L1AIH4in THF (12.89 ml, 12.89 mmol) and
the solution was slowly warmed to room temperature and stirred for 2 hours.
Water (0.5 ml) was slowly added, followed by 15% aqueous NaOH (0.5 ml)
and water (0.5 ml) and the mixture was stirred for 1 hour. The reaction was
filtered over celite and volatiles were removed under reduced pressure to
provide intermediate 6-b as yellow oil.
26

CA 02787472 2012-08-22
Step 2: Intermediate 6-c
To a solution of intermediate 5-g (1.42 g, 5.89 mmol) and intermediate 6-b
(1.0 g, 8.84 mmol) in THF (20 ml) were sequentially added
triphenylphosphine (2.31 g, 8.84 mmol) and DIAD (1.71 ml, 8.84 mmol) at
room temperature and the reaction was then stirred at room temperature for
1 hour. Volatiles were removed under reduced pressure. Purification by silica
gel chromatography provided intermediate 6-c as yellow oil.
Step 3: Intermediate 6-d
To a solution of intermediate 6-c (1.10 g, 3.26 mmol) in THF (32 ml) was
added a 1.0 M solution of TBAF in THF (3.59 ml, 3.59 mmol) and the reaction
was stirred at room temperature for 1 hour. A saturated aqueous solution of
ammonium chloride and ethyl acetate were added, the organic layer was
separated, washed with brine, dried over MgSO4, filtered and concentrated
under reduced pressure. Purification by silica gel chromatography provided
intermediate 6-d as yellow oil.
Step 8: Compound 9
To a solution of intermediate 6-d (181 mg, 0.81 mmol), intermediate 2-g
(330 mg, 0.81 mmol) in 1,4-dioxane, was added cesium carbonate (794 mg,
2.43 mmol), N-N-dimethylaminoglycine (126 mg, 1.22 mmol) and copper (I)
iodide (77 mg, 0.40 mmol). The reaction was degassed with argon for 10
minutes, stirred at reflux for 24 hours and then cooled to room temperature.
Water and ethyl acetate were added, the organic layer was separated, the
aqueous layer was extracted twice with ethyl acetate, the combined organic
extracts were washed with brine, dried over MgSO4, filtered and concentrated
under reduced pressure. Purification by reverse phase chromatography
eluting with 1% HCl/methanol gradient provided compound 9=FICI as yellow
solid. MS (m/z) M+H= 502.2
27

CA 02787472 2012-08-22
Synthesis of Compound 10:
N N
5-g
Ph3P, DIAD F 0j-N TBAF F lei OC-
11
_____________ i 1 _________ y
,
N lel 1
HO\____E
N OTBDMS OH
I
7-a 7-b 7-c
N
HN eI OjNi
l 1 0 lel 1
0 N -7j.OH F
0
SI 40
0 N Cul, Cs2CO3 HN
2-g 0 0
7-c Compound 10
0 N I
Scheme 7
Step 1: Intermediate 7-b
To a solution of intermediate 5-g (3.02 g, 12.46 mmol) and intermediate 7-a
(1.53 g, 13.71 mmol) in THF (20 ml) were sequentially added
triphenylphosphine (3.92 g, 14.95 mmol) and DIAD (2.91 ml, 14.95 mmol)
at room temperature and the reaction was then stirred at room temperature
overnight. Volatiles were removed under reduced pressure. Purification by
silica gel chromatography provided intermediate 7-c as yellow oil.
Step 2: Intermediate 7-c
To a solution of intermediate 7-b (4.0 g, 11.89 mmol) in THF (60 ml) was
added a 1.0 M solution of TBAF in THF (14.3 ml, 14.3 mmol) and the reaction
was stirred at room temperature for 1 hour. A saturated aqueous solution of
ammonium chloride and ethyl acetate were added, the organic layer was
separated, washed with brine, dried over MgSO4, filtered and concentrated
28

CA 02787472 2012-08-22
under reduced pressure. Purification by silica gel chromatography provided
intermediate 7-c as white solid.
Step 3: Compound 10
To a solution of intermediate 7-c (200 mg, 0.90 mmol), intermediate 2-g
(366 mg, 0.90 mmol) in 1,4-dioxane, was added cesium carbonate (880 mg,
2.70 mmol), N-N-dimethylaminoglycine (139 mg, 1.35 mmol) and copper (I)
iodide (86 mg, 0.45 mmol). The reaction was degassed with argon for 10
minutes, stirred at reflux for 24 hours and then cooled to room temperature.
Water and ethyl acetate were added, the organic layer was separated, the
aqueous layer was extracted twice with ethyl acetate, the combined organic
extracts were washed with brine, dried over MgSO4, filtered and concentrated
under reduced pressure. Purification by reverse phase chromatography
eluting with 1% HCl/methanol gradient provided compound 10=HCI as yellow
solid. MS (m/z) M+H= 501.2
Table 1 summarizes representative compound of Formula 1.
Table 1: Example Compounds of Formula 1
Compound Structure MS (m/z)
40 0
1 0
0 0 [M+H]= 480.2
41'
0
110
29

CA 02787472 2012-08-22
. .
0 0
2 HN
0 0 [M+H]= 479.2
iaV
I
0 N
Ol
0
40 40
HN [M+H]= 504.2
3 0 0
40,
I
N CN
0
1.
N
Ojs
4101
4 0
1.1 [M+H]= 486.1
HN
0 ov
I
0 N
N
() j-s---
5
0 0
[M+H]= 500.1
HN
0 ilv
I
0 N

CA 02787472 2012-08-22
= =
0 0S
F3C
0
6
0 [M+H]= 547.1
HN
0 0/
I
0 N
0
40 I.
NC
0
7
101 [M+H]= 504.1
HN
0 0/
I
0 N
N
F 0
LW j ---
S
0
8
140 [M+H]=518.2
HN
0
.. le
1
0 N
N
F 0
igr -----.
0
9 0
I. [M+Hr=502.2
HN
0
I
0 N
31

CA 027.87472 2012-08-22
. .
N
F
* oj--
N
1
0
WI [M+Hr=501.2
HN
0
4V-
0 N I
0 0 0
11 HN
0 0 [M+Hr=449.2
lar
I
N
1.1
0 0 10
12 HN
0 [M+H]=449.2
140 I
0 N
401
13 0
0 0
HN
o
- N 0 [M+H]=480.2 40
N)
0
5
aiii 0 .
14 0 WI
o
- N 0 [M+H]=481.2 0
N)
0
5
32

CA 02787472 2012-08-22
0
15 HN
00
0 [M+H]=420.2 N
N)
140
0 40
16 HN
I 0 [M+H]=419.2
or
11101
40 0 40
17 0
0 [M+H]=420.2
140
Kinase Binding
Btk Kinase Inhibition Assay
Fluorescence polarization-based kinase assays were performed in 384 well-
plate format using histidine tagged recombinant human full-length Bruton
Agammaglobulinemia Tyrosine Kinase (Btk) and a modified protocol of the
KinEASE TM FP Fluorescein Green Assay supplied from Millipore. Kinase
reaction were performed at room temperature for 60 minutes in presence of
250 i_LM substrate, 10 1AM ATP and variable test article concentrations. The
reaction was stopped with EDTA/kinease detection reagents and the
polarization measured on a Tecan 500 instrument. From the dose-response
curve obtained, the IC50 was calculated using Graph Pad Prisms using a
non linear fit curve. The Km for ATP on each enzyme was experimentally
33

CA 02787472 2012-08-22
determined and the Ki values calculated using the Cheng-Prusoff equation
(see: Cheng Y, Prusoff WH. (1973) Relationship between the inhibition
constant (K1) and the concentration of inhibitor which causes 50 per cent
inhibition (150) of an enzymatic reaction". Biochem Pharmacol 22 (23): 3099-
108).
k, values are reported in Table 2:
Table 2: Inhibition of Btk
Compound 1(1 (nM)
1
A
2
A
3
A
4
A
A
6
A
7
A
34

CA 02787472 2012-08-22
8
A
9
A
A
11
12
13
A
14
A
16
17
A - Less than 100 nM; B - less than 1000 Nm; C - more than 1000 nM

CA 02787472 2012-08-22
Splenic Cell Proliferation Assay
Splenocytes were obtained from 6 week old male CD1 mice (Charles River
Laboratories Inc.). Mouse spleens were manually disrupted in PBS and
filtered using a 70um cell strainer followed by ammonium chloride red blood
cell lysis. Cells were washed, resuspended in Splenocyte Medium (HyClone
RPMI supplemented with 10% heat-inactivated FBS, 0.5X non-essential
amino acids, 10mM HEPES, 50uM beta mercaptoethanol) and incubated at 37
C, 5% CO2 for 2h to remove adherent cells. Suspension cells were seeded in
96 well plates at 50,000 cells per well and incubated at 37 C, 5% CO2 for 1h.
Splenocytes were pre-treated in triplicate with 10,000 nM curves of Formula
1 compounds for 1h, followed by stimulation of B cell proliferation with
2.5ug/m1 anti-IgM F(ab1)2 (Jackson ImmunoResearch) for 72h. Cell
proliferation was measured by Cell Titer-Glo Luminescent Assay (Promega).
EC50 values (50% proliferation in the presence of compound as compared to
vehicle treated controls) were calculated from dose response compound
curves using GraphPad Prism Software.
EC50 values are reported in Table 3:
Table 3: Inhibition of splenic cell proliferation
Compound EC50
1
2
3
36

CA 02787472 2012-08-22
4
6
7
8
9
11
12
13
14
37

CA 02787472 2012-08-22
16
17
a - Less than 100 nM; b - less than 1000 nM, c - more than 1000 nM
38

Sorry, the representative drawing for patent document number 2787472 was not found.

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Administrative Status , Maintenance Fee  and Payment History  should be consulted.

Admin Status

Title Date
Forecasted Issue Date Unavailable
(22) Filed 2012-08-22
(41) Open to Public Inspection 2014-02-22
Dead Application 2015-08-24

Abandonment History

Abandonment Date Reason Reinstatement Date
2014-08-22 FAILURE TO PAY APPLICATION MAINTENANCE FEE

Payment History

Fee Type Anniversary Year Due Date Amount Paid Paid Date
Filing $400.00 2012-08-22
Current owners on record shown in alphabetical order.
Current Owners on Record
PHARMASCIENCE INC.
Past owners on record shown in alphabetical order.
Past Owners on Record
None
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.

To view selected files, please enter reCAPTCHA code :




Filter Download Selected in PDF format (Zip Archive)
Document
Description
Date
(yyyy-mm-dd)
Number of pages Size of Image (KB)
Abstract 2012-08-22 1 7
Description 2012-08-22 37 1,140
Claims 2012-08-22 8 98
Cover Page 2014-03-11 1 23
Correspondence 2012-09-06 1 21
Assignment 2012-08-22 2 79
Correspondence 2012-12-12 1 34